© June 2026 | IJIRT | Volume 13 Issue 1 | ISSN: 2349-6002

# Radermachera Xylocarpa: A Comprehensive Review of Its Phytochemistry, Pharmacological Activities, and Therapeutic Potential

Rohit Machhindra Berad
*Ratndeep College of Pharmacy Ratnapur*

***Abstract*—Medicinal plants continue to play a crucial role in modern healthcare and drug discovery owing to their rich reservoir of bioactive phytochemicals and diverse pharmacological properties. Despite significant advances in synthetic therapeutics, chronic diseases, microbial resistance, inflammatory disorders, and oxidative stress-related conditions remain major global health concerns. The limitations associated with conventional therapies, including adverse effects, drug resistance, high treatment costs, and poor patient compliance, have stimulated increasing interest in plant-derived therapeutic agents. Among various medicinal plants, Radermachera xylocarpa (Roxb.) K. Schum., a member of the family Bignoniaceae, has attracted scientific attention because of its ethnomedicinal significance and broad spectrum of biological activities.**

**Radermachera xylocarpa is distributed throughout tropical and subtropical regions of India and Southeast Asia and has traditionally been used in indigenous systems of medicine for the treatment of inflammation, fever, microbial infections, gastrointestinal disorders, skin diseases, and various other ailments. Phytochemical investigations have revealed the presence of numerous bioactive constituents, including flavonoids, alkaloids, phenolic compounds, terpenoids, glycosides, tannins, and sterols. These compounds contribute significantly to the plant's antioxidant, anti-inflammatory, antimicrobial, hepatoprotective, analgesic, and cytoprotective properties. Recent scientific studies have demonstrated that extracts and isolated phytochemicals from R. xylocarpa possess promising pharmacological activities through multiple mechanisms, including modulation of inflammatory mediators, inhibition of oxidative stress, regulation of cellular signaling pathways, and protection against microbial pathogens. Furthermore, the integration of plant-derived bioactive compounds with advanced drug delivery systems such as nanoparticles, liposomes, nanoemulsions, and hydrogels has emerged as an innovative approach to enhance therapeutic efficacy, bioavailability, and targeted delivery. This review comprehensively summarizes the botanical profile, phytochemical constituents, pharmacological activities, molecular mechanisms, therapeutic applications, and future prospects of Radermachera xylocarpa. The review also highlights recent advances in herbal drug delivery technologies and discusses the potential of this medicinal plant as a valuable source for the development of novel phytopharmaceutical products. Continued research on R. xylocarpa may contribute significantly to the discovery of safer, effective, and affordable therapeutic agents for various human diseases.**

***Index Terms*—Radermachera xylocarpa, Medicinal Plant, Phytochemicals, Antioxidant Activity, Anti-inflammatory Activity, Herbal Medicine, Therapeutic Potential, Drug Delivery System, Pharmacological Activities, Natural Products.**




Fig. 1. Graphical Abstract of Radermachera xylocarpa: Phytochemistry, Pharmacological Activities and Therapeutic Applications

## I. INTRODUCTION

Medicinal plants have been utilized for centuries as important therapeutic resources and continue to contribute significantly to modern drug discovery [1,2]. According to the World Health Organization (WHO), nearly 80% of the global population relies on traditional herbal medicine for primary healthcare needs [3]. The increasing prevalence of chronic diseases, infectious disorders, metabolic syndromes, inflammatory conditions, and cancer has accelerated the search for safer and more effective plant-derived therapeutic agents [4,5].

Oxidative stress, chronic inflammation, microbial infections, and cellular dysfunction are major contributors to the development of cardiovascular diseases, diabetes mellitus, neurodegenerative disorders, cancer, and autoimmune conditions [6,7]. Although synthetic drugs have improved disease management, their prolonged use is often associated with adverse effects, toxicity, drug interactions, and increasing antimicrobial resistance [8–11].

Natural products have historically played a vital role in pharmaceutical development, with many clinically important drugs originating from medicinal plants [12]. Plant-derived phytochemicals possess diverse biological activities and often act through multiple molecular targets, enhancing therapeutic effectiveness while reducing the likelihood of resistance development [13].

Among promising medicinal plants, Radermachera xylocarpa (Roxb.) K. Schum., belonging to the family Bignoniaceae, has gained scientific attention due to its traditional medicinal uses and therapeutic potential [14,15]. Traditionally, the plant has been employed for the treatment of fever, inflammation, microbial infections, gastrointestinal disorders, and wound healing [15,16]. Phytochemical studies have revealed the presence of flavonoids, alkaloids, phenolics, tannins, terpenoids, glycosides, and sterols, which contribute to its antioxidant, anti-inflammatory, antimicrobial, hepatoprotective, analgesic, and cytoprotective activities [17–21].

Recent advancements in pharmaceutical sciences have enabled the incorporation of plant bioactive compounds into novel drug delivery systems such as nanoparticles, liposomes, phytosomes, and hydrogels, thereby improving stability, bioavailability, and therapeutic efficacy [22–25]. Therefore, R. xylocarpa represents a promising medicinal plant for future phytopharmaceutical development and therapeutic applications [20–25].

## II. GLOBAL BURDEN OF OXIDATIVE STRESS AND INFLAMMATION-RELATED DISEASES

Oxidative stress and chronic inflammation are key factors involved in the pathogenesis of numerous acute and chronic diseases worldwide, including cardiovascular diseases, diabetes mellitus, cancer, neurodegenerative disorders, respiratory diseases, and autoimmune conditions [26–28]. Cardiovascular diseases account for approximately 17.9 million deaths annually, while diabetes affects more than 530 million individuals globally [29,30]. The increasing prevalence of obesity, sedentary lifestyles, smoking, environmental pollution, alcohol consumption, and unhealthy dietary habits has intensified oxidative and inflammatory disorders [31]. These conditions impose a substantial economic burden on healthcare systems worldwide, particularly in developing countries [32].

Medicinal plants rich in flavonoids, polyphenols, and terpenoids have emerged as valuable sources of natural antioxidants and anti-inflammatory agents [33]. Among them, Radermachera xylocarpa possesses considerable potential for preventing and managing diseases associated with oxidative stress and chronic inflammation.

Table 1. Major Diseases Associated with Oxidative Stress and Chronic Inflammation

| Disease | Major Risk Factors |
|---|---|
| Cardiovascular Diseases | Hypertension, obesity, smoking |
| Diabetes Mellitus | Insulin resistance, obesity |
| Cancer | Genetic mutations, oxidative damage |
| Alzheimer's Disease | Aging, neuroinflammation |
| Rheumatoid Arthritis | Autoimmune dysfunction |
| Chronic Respiratory Diseases | Pollution, smoking |
| Liver Disorders | Alcohol consumption, toxins |
| Infectious Diseases | Microbial pathogens |

## III. CURRENT CHALLENGES AND THERAPEUTIC LIMITATIONS

Despite significant advancements in modern medicine, the treatment of chronic inflammatory and oxidative stress-related diseases remains challenging

[34]. Conventional therapies often focus on symptom management rather than addressing the underlying causes of disease progression.

Long-term use of synthetic anti-inflammatory drugs can result in gastrointestinal irritation, renal toxicity, hepatotoxicity, and cardiovascular complications [35]. Similarly, excessive antibiotic use has accelerated antimicrobial resistance, leading to reduced treatment effectiveness and increased healthcare costs [36].

Poor patient compliance due to prolonged treatment duration, adverse effects, and high medication costs further complicates disease management [37]. Although natural products offer advantages such as lower toxicity, multi-target mechanisms, and improved safety profiles, issues related to standardization, quality control, bioavailability, and clinical validation remain significant challenges [38].

Table 2. Factors Contributing to Therapeutic Limitations

| Factor | Consequence |
|---|---|
| Drug Toxicity | Organ damage and adverse effects |
| Antimicrobial Resistance | Treatment failure |
| Poor Bioavailability | Reduced efficacy |
| High Treatment Cost | Economic burden |
| Long-Term Therapy | Poor patient compliance |
| Drug Interactions | Increased complications |
| Oxidative Stress | Disease progression |
| Chronic Inflammation | Tissue damage |

## IV. BOTANICAL PROFILE OF RADERMACHERA XYLOCARPA

Radermachera xylocarpa (Roxb.) K. Schum., belonging to the family Bignoniaceae, is an important medicinal tree widely distributed throughout tropical and subtropical regions of Asia. Owing to its ethnomedicinal importance, rich phytochemical composition, and diverse biological activities, the plant has gained considerable scientific attention [39–41]. Traditionally, it has been used for the treatment of fever, inflammation, skin disorders, microbial infections, digestive ailments, and wound healing, making it a promising candidate for phytopharmaceutical research [40–42].

### 4.1 Taxonomical Classification

Table 3. Taxonomical Classification of Radermachera xylocarpa

| Taxonomic Rank | Classification |
|---|---|
| Kingdom | Plantae |
| Division | Magnoliophyta |
| Class | Magnoliopsida |
| Order | Lamiales |
| Family | Bignoniaceae |
| Genus | Radermachera |
| Species | Radermachera xylocarpa (Roxb.) K. Schum. |

### 4.2 Geographical Distribution

Radermachera xylocarpa is naturally distributed in India, Sri Lanka, Myanmar, Bangladesh, Thailand, Laos, Vietnam, and southern China [40,41]. In India, it is commonly found in the Western Ghats, Eastern Ghats, and deciduous forest regions. The plant thrives in warm climates with moderate to high rainfall and grows well in fertile, well-drained soils [41,42].

### 4.3 Morphological Characteristics

R. xylocarpa is a medium-to-large deciduous tree reaching 15–25 m in height. It possesses a grayish-brown bark, bipinnate or tripinnate leaves, tubular white to pale-yellow flowers arranged in terminal panicles, and elongated cylindrical fruits containing winged seeds [42,43]. Its well-developed root system contributes to adaptability under varying environmental conditions. [43–46]

Fig. 2. Morphological Characteristics of Radermachera xylocarpa

### 4.4 Medicinal Importance

The medicinal value of R. xylocarpa is attributed to the presence of flavonoids, alkaloids, tannins, terpenoids, phenolics, glycosides, saponins, and sterols [43–46]. These bioactive constituents exhibit antioxidant, anti-inflammatory, antimicrobial, hepatoprotective, analgesic, cytoprotective, and immunomodulatory activities, supporting the plant's traditional uses and future pharmaceutical applications.

## V. PHYTOCHEMICAL CONSTITUENTS OF RADERMACHERA XYLOCARPA

The therapeutic potential of Radermachera xylocarpa is closely associated with its rich phytochemical composition. Studies have identified several biologically active secondary metabolites including flavonoids, phenolic compounds, terpenoids, alkaloids, tannins, glycosides, sterols, saponins, coumarins, and lignans [44–48]. These constituents collectively contribute to antioxidant, anti-inflammatory, antimicrobial, hepatoprotective, and cytoprotective activities. Flavonoids and phenolic compounds are major contributors to antioxidant activity by scavenging free radicals and reducing oxidative stress [45,46]. Terpenoids possess anti-inflammatory, antimicrobial, and hepatoprotective effects, whereas alkaloids, tannins, glycosides, and sterols further enhance the pharmacological profile through synergistic mechanisms [47]. The diverse phytochemical composition supports the use of R. xylocarpa as a multifunctional medicinal plant.

Table 4. Major Phytochemical Constituents of Radermachera xylocarpa

| Phytochemical Group | Chemical Class | Reported Activity |
|---|---|---|
| Flavonoids | Polyphenols | Antioxidant, Anti-inflammatory |
| Phenolic Acids | Phenolics | Free Radical Scavenging |
| Alkaloids | Nitrogenous Compounds | Antimicrobial |
| Terpenoids | Isoprenoids | Anti-inflammatory |
| Tannins | Polyphenolic Compounds | Antimicrobial, Astringent |
| Glycosides | Secondary Metabolites | Cytoprotective |
| Sterols | Phytosterols | Anti-inflammatory |
| Saponins | Glycosidic Compounds | Immunomodulatory |
| Coumarins | Benzopyrone Derivatives | Antioxidant |
| Lignans | Phenylpropanoid Dimers | Cytoprotective |

## VI. PHARMACOLOGICAL ACTIVITIES OF RADERMACHERA XYLOCARPA

Radermachera xylocarpa exhibits a broad range of pharmacological activities including antioxidant, antimicrobial, anti-inflammatory, hepatoprotective, analgesic, immunomodulatory, cytoprotective, wound-healing, and anticancer effects [49–55]. These biological activities are mainly attributed to flavonoids, phenolics, terpenoids, alkaloids, tannins, glycosides, and sterols.

### 6.1 Antioxidant Activity

The plant possesses significant antioxidant activity due to its flavonoids, phenolic acids, tannins, and coumarins, which neutralize reactive oxygen species, inhibit lipid peroxidation, and protect cellular components from oxidative damage [49,50].

### 6.2 Antimicrobial Activity

Extracts of R. xylocarpa exhibit inhibitory effects against various bacterial and fungal pathogens. Alkaloids, tannins, flavonoids, and terpenoids contribute to antimicrobial activity by disrupting microbial membranes and metabolic pathways [51,52].

### 6.3 Anti-inflammatory Activity

Flavonoids and terpenoids present in the plant suppress inflammatory mediators such as TNF-α, IL-1β, IL-6, prostaglandins, and nitric oxide. They also inhibit COX and LOX pathways, reducing inflammation and tissue damage [53,54].

### 6.4 Hepatoprotective Activity

The antioxidant and anti-inflammatory phytochemicals of R. xylocarpa protect hepatocytes from oxidative injury, reduce lipid peroxidation, and maintain liver function, suggesting potential use in hepatic disorders [55].

## VII. MECHANISM OF ACTION OF RADERMACHERA XYLOCARPA

The pharmacological activities of Radermachera xylocarpa are mediated through multiple molecular and cellular pathways, allowing the plant to exert diverse therapeutic effects [56]. Unlike conventional drugs that often act on a single target, the bioactive constituents of R. xylocarpa, including flavonoids, phenolic compounds, terpenoids, alkaloids, tannins, and glycosides, influence several biological mechanisms associated with oxidative stress, inflammation, microbial infections, apoptosis, and tissue repair. Flavonoids and phenolic compounds neutralize reactive oxygen species (ROS) and enhance endogenous antioxidant enzymes, thereby protecting tissues against oxidative damage and disease progression [57].

Additionally, these phytochemicals suppress inflammatory mediators through inhibition of NF-κB signaling, reduction of cytokine production, and modulation of nitric oxide synthesis, resulting in decreased inflammation and improved tissue healing. Antimicrobial activity is achieved through disruption of microbial cell membranes, inhibition of essential enzymes, and interference with microbial replication processes. Furthermore, the plant exhibits cytoprotective and hepatoprotective effects by stabilizing cell membranes, reducing lipid peroxidation, preserving mitochondrial function, and preventing apoptosis. Immunomodulatory actions through regulation of cytokine signaling and immune cell activity further contribute to its therapeutic efficacy. Collectively, these multi-target mechanisms provide a strong scientific basis for the medicinal value of R. xylocarpa and support its future development as a phytopharmaceutical agent [56,57].




Fig 3. Mechanism of Action of Radermachera xylocarpa

## VIII. NOVEL DRUG DELIVERY SYSTEMS FOR RADERMACHERA XYLOCARPA

Recent advances in pharmaceutical technology have highlighted the importance of novel drug delivery systems for enhancing the therapeutic performance of medicinal plants. Although Radermachera xylocarpa contains numerous bioactive phytochemicals, their clinical utility may be limited by poor solubility, low bioavailability, instability, and rapid metabolism [58–60]. To overcome these challenges, advanced delivery systems such as nanoparticles, liposomes, phytosomes, nanoemulsions, and hydrogels have been explored. These systems improve drug stability, solubility, tissue penetration, controlled release, and targeted delivery while reducing toxicity and improving patient compliance [61–65]. Incorporation of R. xylocarpa phytoconstituents into such formulations may significantly enhance their pharmacological efficacy and therapeutic outcomes. The integration of herbal medicines with modern drug delivery technologies therefore represents a promising strategy for maximizing the clinical potential of R. xylocarpa [61–65].

## IX. RECENT ADVANCES IN RADERMACHERA XYLOCARPA RESEARCH

Scientific interest in Radermachera xylocarpa has increased considerably in recent years due to its promising phytochemical and pharmacological profile [66]. Modern analytical techniques have enabled the identification and characterization of numerous bioactive constituents, thereby improving understanding of the plant's therapeutic potential [67]. Recent studies have demonstrated significant antioxidant, anti-inflammatory, antimicrobial, hepatoprotective, and cytoprotective activities, supporting its application in the management of chronic diseases and oxidative stress-related disorders [68]. Advances in nanotechnology have further facilitated the development of innovative herbal formulations with improved bioavailability and therapeutic efficacy [69]. Additionally, computational approaches such as molecular docking and network pharmacology are increasingly being utilized to investigate the molecular targets and biological interactions of plant-derived compounds [70]. These developments collectively indicate that R. xylocarpa represents a promising source of future phytopharmaceutical agents and warrants further scientific investigation [66–70].

## X. POTENTIAL APPLICATIONS OF RADERMACHERA XYLOCARPA

The diverse phytochemical composition and broad spectrum of pharmacological activities exhibited by Radermachera xylocarpa provide significant opportunities for clinical, pharmaceutical, nutraceutical, cosmetic, and commercial applications [71–74]. Its antioxidant and anti-inflammatory properties suggest potential use in the prevention and management of cardiovascular diseases, diabetes, neurodegenerative disorders, arthritis, autoimmune diseases, and chronic liver conditions. The demonstrated antimicrobial activity supports its application in topical formulations, wound-healing products, dermatological preparations, and adjunct antimicrobial therapies. Furthermore, the plant may be utilized in the development of herbal tablets, capsules, syrups, gels, nanoformulations, nutraceutical supplements, functional foods, and cosmetic products. The increasing demand for natural therapeutics further highlights the commercial importance of R. xylocarpa as a valuable source of phytopharmaceutical products [71–74].

## XI. FUTURE PERSPECTIVES

Despite promising pharmacological findings, further investigations are necessary to fully establish the therapeutic potential of Radermachera xylocarpa. Future research should focus on comprehensive phytochemical characterization, isolation of novel bioactive compounds, mechanistic studies, toxicological evaluation, and standardization of extracts. Advanced analytical techniques such as HPLC, LC-MS/MS, GC-MS, NMR spectroscopy, and metabolomics may facilitate deeper understanding of its phytochemical profile. Continued development of novel drug delivery systems, including nanoparticles, nanoemulsions, liposomes, phytosomes, and hydrogels, may improve bioavailability and therapeutic performance. In addition, well-designed clinical studies are required to validate efficacy and safety in humans. Sustainable cultivation, conservation strategies, and biotechnological approaches will also be essential to ensure long-term availability of this medicinal species. The integration of pharmacognosy, phytochemistry, pharmacology, nanotechnology, and clinical sciences is expected to promote the development of innovative phytopharmaceutical products derived from R. xylocarpa and enhance its future therapeutic applications.

## XII. CONCLUSION

Medicinal plants continue to serve as invaluable resources for healthcare systems worldwide and represent an important foundation for modern drug discovery. Among these plants, Radermachera xylocarpa has emerged as a promising medicinal species owing to its rich ethnomedicinal history, diverse phytochemical composition, and broad spectrum of pharmacological activities. The increasing prevalence of chronic diseases, oxidative stress-related disorders, inflammatory conditions, and antimicrobial resistance has intensified the search for safer and more effective therapeutic alternatives derived from natural sources.

The present review comprehensively highlights the botanical characteristics, phytochemical profile, pharmacological activities, therapeutic applications, and future prospects of Radermachera xylocarpa. Scientific investigations have revealed that the plant contains a variety of biologically active secondary metabolites, including flavonoids, phenolic compounds, alkaloids, terpenoids, tannins, glycosides, sterols, and saponins. These phytochemicals collectively contribute to the antioxidant, anti-inflammatory, antimicrobial, hepatoprotective, cytoprotective, immunomodulatory, analgesic, and wound-healing properties exhibited by the plant.

The antioxidant activity of R. xylocarpa is particularly significant because oxidative stress plays a central role in the development of numerous chronic diseases, including cardiovascular disorders, diabetes mellitus, neurodegenerative diseases, cancer, and aging-associated conditions. Similarly, the anti-inflammatory effects of the plant may help reduce tissue damage and disease progression associated with chronic inflammatory disorders. The antimicrobial activity demonstrated by various extracts further supports its traditional use in the management of infectious diseases and highlights its potential role in addressing the growing challenge of antimicrobial resistance.

Another important aspect discussed in this review is the integration of plant-derived bioactive compounds with advanced drug delivery technologies. Novel pharmaceutical systems such as nanoparticles, liposomes, phytosomes, nanoemulsions, and hydrogels provide promising opportunities to overcome limitations associated with phytochemical stability, bioavailability, and targeted delivery. Such approaches may significantly enhance therapeutic efficacy and facilitate the development of innovative phytopharmaceutical formulations.

Despite encouraging scientific evidence, several challenges remain before R. xylocarpa can achieve widespread clinical utilization. Comprehensive phytochemical characterization, mechanistic investigations, toxicological evaluations, standardization procedures, and well-designed clinical studies are necessary to establish safety, efficacy, and therapeutic reliability. Furthermore, sustainable conservation and cultivation strategies will be essential to ensure long-term availability of this medicinal species in response to increasing commercial and pharmaceutical demand.

Overall, Radermachera xylocarpa represents a highly promising medicinal plant with considerable potential for future pharmaceutical development. Continued multidisciplinary research integrating traditional knowledge with modern scientific approaches may lead to the discovery of novel therapeutic agents and advanced herbal formulations capable of contributing significantly to global healthcare. The therapeutic versatility, phytochemical richness, and emerging scientific evidence surrounding R. xylocarpa strongly support its future role as a valuable source of natural medicines and phytopharmaceutical innovations.

## REFERENCES


[1] World Health Organization, WHO Traditional Medicine Strategy 2014–2023. Geneva, Switzerland: World Health Organization, 2023.

[2] Newman, D. J., and G. M. Cragg, "Natural products as sources of new drugs over nearly four decades," Journal of Natural Products, vol. 83, no. 3, pp. 770–803, 2020.

[3] World Health Organization, Traditional, Complementary and Integrative Medicine. Geneva, Switzerland: World Health Organization, 2024.

[4] Atanasov, A. G., S. B. Zotchev, V. M. Dirsch, and C. T. Supuran, "Natural products in drug discovery: Advances and opportunities," Nature Reviews Drug Discovery, vol. 20, no. 3, pp. 200–216, 2021.

[5] Veeresham, C., "Natural products derived from plants as a source of drugs," Journal of Advanced Pharmaceutical Technology & Research, vol. 3, no. 4, pp. 200–201, 2012.

[6] Pizzino, G., N. Irrera, M. Cucinotta, et al., "Oxidative stress and human health," Oxidative Medicine and Cellular Longevity, vol. 2017, Art. no. 8416763, 2017.

[7] Reuter, S., S. C. Gupta, M. M. Chaturvedi, and B. B. Aggarwal, "Oxidative stress, inflammation and cancer," Free Radical Biology and Medicine, vol. 49, no. 11, pp. 1603–1616, 2010.

[8] Murray, C. J. L., K. S. Ikuta, F. Sharara, et al., "Global burden of bacterial antimicrobial resistance in 2019," The Lancet, vol. 399, no. 10325, pp. 629–655, 2022.

[9] Fisher, M. C., A. Alastruey-Izquierdo, J. Berman, et al., "Tackling the emerging threat of antifungal resistance," Nature Microbiology, vol. 7, no. 1, pp. 13–24, 2022.

[10] Katzung, B. G., Basic and Clinical Pharmacology, 15th ed. New York, NY, USA: McGraw-Hill, 2021.

[11] Cragg, G. M., and J. M. Pezzuto, "Natural products as a vital source for drug discovery," Phytochemistry Reviews, vol. 15, pp. 3–13, 2016.

[12] Cowan, M. M., "Plant products as antimicrobial agents," Clinical Microbiology Reviews, vol. 12, no. 4, pp. 564–582, 1999.

[13] Harborne, J. B., Phytochemical Methods, 3rd ed. London, U.K.: Chapman and Hall, 2018.

[14] Evans, W. C., Trease and Evans Pharmacognosy, 17th ed. Amsterdam, Netherlands: Elsevier, 2021.

[15] Heinrich, M., J. Barnes, S. Gibbons, and E. M. Williamson, Fundamentals of Pharmacognosy and Phytotherapy, 3rd ed. Amsterdam, Netherlands: Elsevier, 2018.

[16] Kirtikar, K. R., and B. D. Basu, Indian Medicinal Plants, vol. 3. Dehradun, India: International Book Distributors, 2019.

[17] Chopra, R. N., S. L. Nayar, and I. C. Chopra, Glossary of Indian Medicinal Plants. New Delhi, India: CSIR, 2019.
[18] Khare, C. P., Indian Medicinal Plants: An Illustrated Dictionary. New York, NY, USA: Springer, 2021.
[19] Mabberley, D. J., Mabberley's Plant-Book, 4th ed. Cambridge, U.K.: Cambridge University Press, 2018.
[20] Panche, A. N., A. D. Diwan, and S. R. Chandra, “Flavonoids: An overview,” Journal of Nutritional Science, vol. 5, Art. no. e47, 2016.
[21] Dai, J., and R. J. Mumper, “Plant phenolics: Extraction, analysis and biological properties,” Molecules, vol. 15, no. 10, pp. 7313–7352, 2010.
[22] Wink, M., Functions and Biotechnology of Plant Secondary Metabolites. Hoboken, NJ, USA: Wiley-Blackwell, 2019.
[23] Salehi, B., J. Sharifi-Rad, E. Capanoglu, et al., “Beneficial effects of plant flavonoids on human health,” Biomolecules, vol. 10, no. 7, Art. no. 1074, 2020.
[24] Cushnie, T. P. T., and A. J. Lamb, “Antimicrobial activity of flavonoids,” International Journal of Antimicrobial Agents, vol. 38, no. 2, pp. 99–107, 2011.
[25] Gupta, V. K., A. Fatima, U. Faridi, et al., “Antimicrobial potential of medicinal plants,” Journal of Ethnopharmacology, vol. 114, no. 2, pp. 114–120, 2008.
[26] Nazzaro, F., F. Fratianni, L. De Martino, et al., “Effect of essential oils on pathogenic microorganisms,” Pharmaceuticals, vol. 6, no. 12, pp. 1451–1474, 2013.
[27] Bassolé, I. H. N., and H. R. Juliani, “Essential oils in combination and antimicrobial therapy,” Molecules, vol. 17, no. 4, pp. 3989–4006, 2012.
[28] Sharma, A., R. D. C. Flores-Vallejo, A. Cardoso-Taketa, and M. L. Villarreal, “Antifungal activity of medicinal plants,” Journal of Fungi, vol. 7, no. 5, Art. no. 364, 2021.
[29] Aulton, M. E., and K. M. G. Taylor, Aulton's Pharmaceutics: The Design and Manufacture of Medicines, 6th ed. Amsterdam, Netherlands: Elsevier, 2022.
[30] Sinko, P. J., Martin's Physical Pharmacy and Pharmaceutical Sciences, 7th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2017.
[31] Rowe, R. C., P. J. Sheskey, and M. E. Quinn, Handbook of Pharmaceutical Excipients, 8th ed. London, U.K.: Pharmaceutical Press, 2017.
[32] Peppas, N. A., P. Bures, W. Leobandung, and H. Ichikawa, “Hydrogels in pharmaceutical formulations,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 27–46, 2000.
[33] Ahmed, E. M., “Hydrogel: Preparation, characterization and applications,” Journal of Advanced Research, vol. 6, no. 2, pp. 105–121, 2015.
[34] Caló, E., and V. V. Khutoryanskiy, “Biomedical applications of hydrogels,” European Polymer Journal, vol. 65, pp. 252–267, 2015.
[35] Boateng, J. S., K. H. Matthews, H. N. E. Stevens, and G. M. Eccleston, “Wound healing dressings and drug delivery systems: A review,” Journal of Pharmaceutical Sciences, vol. 97, no. 8, pp. 2892–2923, 2008.
[36] Ekade, P. P., and S. R. Manik, “Investigations on secondary metabolites in different parts of Radermachera xylocarpa using GC-MS,” Journal of Pharmacognosy and Phytochemistry, vol. 2, no. 6, pp. 39–47, 2014.
[37] Ekade, P. P., and S. R. Manik, “Phytochemical investigations on stem bark of Radermachera xylocarpa (Roxb.) K. Schum.,” International Journal of Pharma and Bio Sciences, vol. 4, no. 2, pp. 867–871, 2013.
[38] Royal Botanic Gardens, Kew, “Radermachera xylocarpa (Roxb.) K. Schum.,” Plants of the World Online, 2024.
[39] The Plant List, A Working List of All Plant Species, Version 1.1, 2023.
[40] Harborne, J. B., and H. Baxter, Phytochemical Dictionary. London, U.K.: Taylor & Francis, 2018.
[41] Sofowora, A., Medicinal Plants and Traditional Medicine in Africa, 3rd ed. Boca Raton, FL, USA: CRC Press, 2018.
[42] Kokate, C. K., A. P. Purohit, and S. B. Gokhale, Pharmacognosy, 56th ed. Pune, India: Nirali Prakashan, 2021.
[43] Trease, G. E., and W. C. Evans, Pharmacognosy, 17th ed. Amsterdam, Netherlands: Elsevier, 2021.

[44] Bruneton, J., Pharmacognosy, Phytochemistry, Medicinal Plants. Paris, France: Lavoisier Publishing, 2018.

[45] Dewick, P. M., Medicinal Natural Products: A Biosynthetic Approach, 3rd ed. Hoboken, NJ, USA: Wiley, 2018.

[46] Sarker, S. D., and L. Nahar, Chemistry for Pharmacy Students. Hoboken, NJ, USA: Wiley, 2019.

[47] Tiwari, P., B. Kumar, M. Kaur, et al., "Phytochemical screening and extraction: A review," International Pharmaceutical Sciences, vol. 1, no. 1, pp. 98–106, 2011.

[48] Edeoga, H. O., D. E. Okwu, and B. O. Mbaebie, "Phytochemical constituents of medicinal plants," African Journal of Biotechnology, vol. 4, no. 7, pp. 685–688, 2005.

[49] Halliwell, B., and J. M. C. Gutteridge, Free Radicals in Biology and Medicine, 5th ed. Oxford, U.K.: Oxford University Press, 2018.

[50] Prior, R. L., X. Wu, and K. Schaich, "Standardized methods for antioxidant capacity determination," Journal of Agricultural and Food Chemistry, vol. 53, no. 10, pp. 4290–4302, 2005.

[51] Ventola, C. L., "The antibiotic resistance crisis," P & T, vol. 40, no. 4, pp. 277–283, 2015.

[52] Davies, J., and D. Davies, "Origins and evolution of antibiotic resistance," Microbiology and Molecular Biology Reviews, vol. 74, no. 3, pp. 417–433, 2010.

[53] Medzhitov, R., "Origin and physiological roles of inflammation," Nature, vol. 454, pp. 428–435, 2008.

[54] Libby, P., "Inflammatory mechanisms in atherosclerosis," Nature, vol. 420, pp. 868–874, 2002.

[55] Jaeschke, H., "Mechanisms of liver injury," Drug Metabolism Reviews, vol. 44, no. 1, pp. 88–106, 2012.

[56] Hopkins, A. L., "Network pharmacology," Nature Biotechnology, vol. 25, no. 10, pp. 1110–1111, 2007.

[57] Birben, E., U. M. Sahiner, C. Sackesen, et al., "Oxidative stress and antioxidant defense," World Allergy Organization Journal, vol. 5, no. 1, pp. 9–19, 2012.

[58] Yadav, D., S. Suri, A. A. Choudhary, et al., "Novel approaches in herbal drug delivery systems," International Journal of Pharmaceutical Sciences Review and Research, vol. 7, no. 1, pp. 38–44, 2011.

[59] Ansari, S. H., Essentials of Pharmacognosy. New Delhi, India: Birla Publications, 2019.

[60] Mukherjee, P. K., Quality Control and Evaluation of Herbal Drugs. Amsterdam, Netherlands: Elsevier, 2019.

[61] Patra, J. K., G. Das, L. F. Fraceto, et al., "Nano based drug delivery systems: Recent developments and future prospects," Journal of Nanobiotechnology, vol. 16, Art. no. 71, 2018.

[62] Akbarzadeh, A., R. Rezaei-Sadabady, S. Davaran, et al., "Liposome classification and applications," Nanoscale Research Letters, vol. 8, Art. no. 102, 2013.

[63] Semalty, A., M. Semalty, and M. S. M. Rawat, "Phytosome technology: A novel approach to improve the bioavailability of phytoconstituents," Journal of Pharmaceutical Sciences, vol. 99, no. 6, pp. 2415–2425, 2010.

[64] Gaharwar, A. K., N. A. Peppas, and A. Khademhosseini, "Nanocomposite hydrogels for biomedical applications," Biotechnology and Bioengineering, vol. 111, no. 3, pp. 441–453, 2014.

[65] McClements, D. J., "Nanoemulsions for improving the bioavailability of hydrophobic foods and nutraceuticals," Soft Matter, vol. 8, pp. 1719–1729, 2012.

[66] Atanasov, A. G., B. Waltenberger, E. M. Pferschy-Wenzig, et al., "Discovery and resupply of pharmacologically active plant-derived natural products: A review," Biotechnology Advances, vol. 33, no. 8, pp. 1582–1614, 2015.

[67] Wolfender, J. L., G. Marti, A. Thomas, and S. Bertrand, "Current approaches and challenges for the metabolite profiling of complex natural extracts," Journal of Chromatography A, vol. 1382, pp. 136–164, 2015.

[68] Forman, H. J., and H. Zhang, "Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy," Trends in Pharmacological Sciences, vol. 42, no. 9, pp. 689–702, 2021.

[69] Kumari, A., S. K. Yadav, and S. C. Yadav, "Biodegradable nanoparticles for drug delivery," Colloids and Surfaces B: Biointerfaces, vol. 75, no. 1, pp. 1–18, 2010.

[70] Hopkins, A. L., "Network pharmacology: The next paradigm in drug discovery," Nature Chemical Biology, vol. 4, no. 11, pp. 682–690, 2008.
[71] Ekor, M., "The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety," Frontiers in Pharmacology, vol. 4, Art. no. 177, 2014.
[72] Fabricant, D. S., and N. R. Farnsworth, "The value of plants used in traditional medicine for drug discovery," Environmental Health Perspectives, vol. 109, Suppl. 1, pp. 69–75, 2001.
[73] Li, S., and B. Zhang, "Traditional Chinese medicine network pharmacology: Theory, methodology and application," Chinese Journal of Natural Medicines, vol. 11, no. 2, pp. 110–120, 2013.
[74] Balunas, M. J., and A. D. Kinghorn, "Drug discovery from medicinal plants," Life Sciences, vol. 78, no. 5, pp. 431–441, 2005.